COMMUNIQUÉS West-GlobeNewswire

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
09/09/2024
Purchases Signal Leadership Confidence and Commitment to Company ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on [...]
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
09/09/2024
In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage [...]
September 2024 Letter to Shareholders
09/09/2024
VANCOUVER, Washington, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, It continues to be a transformative year for CytoDyn Inc. (“CytoDyn” or the “Company”). A year in which we have made significant strides as a [...]
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
09/09/2024
Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal onset seizures VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals [...]
Intelligent Bio Solutions Inc. Announces Preliminary Full Fiscal Year 2024 Revenue Growth of 148% Year-Over-Year
09/09/2024
- 2024 unaudited revenue growth for the fiscal fourth quarter and full year of approximately 64% and 148% year-over-year, respectively - NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ( [...]
Cassava Sciences Names Rick Barry as Chief Executive Officer
09/09/2024
Claude Nicaise, M.D. appointed Chairman of the Board AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced it [...]
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
09/09/2024
WARREN, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' [...]
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
09/09/2024
TARA-002 demonstrated compelling efficacy and was generally well-tolerated Enrollment in additional cohorts underway with initial results expected in 1H’25 NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara [...]
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
09/09/2024
MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor [...]
Creyon Bio Appoints Venture Capitalists Serge Messerlian and Shaquille Vayda to Board of Directors
09/09/2024
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Creyon Bio , Inc. ("Creyon"), a clinical-stage leader in AI/machine learning-enabled engineering of oligonucleotide-based medicines (OBMs), [...]
SAFE - Nouvel engagement de financement d’un montant minimum net de 3 M€ dans la perspective de la validation du plan de continuation
08/09/2024
Avertissement : La société SAFE SA (la « Société ») a mis en place un financement sous forme d’obligations convertibles en actions nouvelles ou existantes (OCEANE) avec Global Corporate Finance Opportunities 20 (« GCFO [...]
RYBREVANT®▼ (amivantamab) plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
08/09/2024
New longer-term data from the MARIPOSA study confirm superior outcomes of amivantamab plus lazertinib regimen compared to osimertinib monotherapy as first-line therapy 1 Results from an interim analysis featured in late [...]
Avalyn Presents Multiple Posters on AP01 for Pulmonary Fibrosis, Including MIST Phase 2b Trial Design and ATLAS Phase 1b Study Post-hoc Analyses, at ERS 2024
08/09/2024
Trial Design Showcased for the MIST Study, a Recently Initiated Phase 2b Clinical Trial, Evaluating the Efficacy and Safety of AP01 (inhaled pirfenidone) Compared to Placebo in Patients with Progressive Pulmonary [...]
XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders
06/09/2024
CALGARY, Alberta, Sept. 06, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/09/2024
NAARDEN, the Netherlands and MIAMI, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06/09/2024
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08
06/09/2024
PURCHASE, NY, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today announced that it issued an inducement award to a new employee. Effective [...]
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering
06/09/2024
CARLSBAD, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the closing of its previously announced public offering of 14,724,058 shares of common [...]
Elutia Celebrates First Year
06/09/2024
Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting [...]

Pages